News

In this letter, the FDA communicated that an additional Phase 3 clinical trial for MCNA would be necessary to adequately establish MCNA’s efficacy and safety. The FDA also

In addition, the company announced that it is on track to start Phase II clinical testing in the first half of this year, and that the results of

The completion has resulted in various development programs including those that target AMPK, eiF4E, Metnase, MTH1, PERK, and other indications. The company is working with partners to develop

The companies signed a collaboration and licensing agreement in June 2014 for about five programs, including the lead NY-ESO TCR program. GSK can license the program if it

Mission Therapeutics was established in 2011 to commercialize expert research into the ubiquitin pathway to treat cancers and other unmet medical needs. The company built a platform to

The FDA’s Fast Track program facilitates the development and review of drugs intended to treat serious conditions and address an unmet medical need. A drug development program with

The Company also reiterated its previous guidance that it expects to report data from the APOLLO study in 2017, and due to the competitiveness of this timing, it

Matinas BioPharma president and CEO Roelof Rongen said: "The encouraging preclinical data demonstrating MAT2501’s oral bioavailability and its targeted delivery of amikacin directly to the site of infection

Andexanet alfa, which is in Phase 3 clinical development in the U.S. and Europe, is designed to reverse the anticoagulant activity of Factor Xa inhibitors, includingEliquis (apixaban). Bristol-Myers